LivaNova PLC has updated its 2026 guidance, projecting 9-10% revenue growth and 14% adjusted EPS growth, driven by strong demand in its cardiopulmonary and neuromodulation segments. The company is expanding production capacity to meet oxygenator demand, which currently exceeds supply, and is gaining market share. Additionally, LivaNova is preparing for the launch of its obstructive sleep apnea (OSA) product in 2027, which is expected to benefit from favorable reimbursement conditions. The company trades at a sector-average valuation with potential upside as legacy liabilities are resolved and new products launch.
LivaNova's updated 2026 guidance projects 9-10% revenue growth and 14% adjusted EPS growth as it prepares for the launch of its obstructive sleep apnea product. For readers following the health sector, here is Pluang's market snapshot as of Nov 12, 2026 22:11 WIB: out of 150 priced US health stocks, 42 rose and 108 fell today. Notable movers include TNGX at USD 24.24 with a -5.79% change and a typical hold time of 4 days, BFLY at USD 6.73 down 5.74% with a 16-day hold, and CGC at USD 0.57 down 5.70% with a 40-day hold and 99% buy order activity.
TRM Labs introduced the Disruption Awards to recognize coalitions of public and private organizations that successfully disrupted major cybercrimes in 2026. Winners include groups that took down a phishing service responsible for most Microsoft-block...
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
atQor has been named a finalist for the 2026 Microsoft Partner of the Year Award in the Agents category, recognized for its innovative and scalable agentic AI solutions deployed across nine industries. The company developed 252 AI agents in FY26, wit...
